- Home
- PALI vs SNGX Comparison
PALI vs SNGX Comparison
Compare PALI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- SNGX
- Stock Information
- Founded
- PALI 1996
- SNGX 1987
- Country
- PALI United States
- SNGX United States
- Employees
- PALI N/A
- SNGX N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- SNGX Health Care
- Exchange
- PALI Nasdaq
- SNGX Nasdaq
- Market Cap
- PALI 3.7M
- SNGX 4.3M
- IPO Year
- PALI N/A
- SNGX 1987
- Fundamental
- Price
- PALI $1.01
- SNGX $2.74
- Analyst Decision
- PALI Strong Buy
- SNGX Strong Buy
- Analyst Count
- PALI 2
- SNGX 1
- Target Price
- PALI $12.00
- SNGX $6.00
- AVG Volume (30 Days)
- PALI 1.1M
- SNGX 19.3M
- Earning Date
- PALI 08-11-2025
- SNGX 08-12-2025
- Dividend Yield
- PALI N/A
- SNGX N/A
- EPS Growth
- PALI N/A
- SNGX N/A
- EPS
- PALI N/A
- SNGX N/A
- Revenue
- PALI N/A
- SNGX $2,342.00
- Revenue This Year
- PALI N/A
- SNGX N/A
- Revenue Next Year
- PALI N/A
- SNGX N/A
- P/E Ratio
- PALI N/A
- SNGX N/A
- Revenue Growth
- PALI N/A
- SNGX N/A
- 52 Week Low
- PALI $0.60
- SNGX $1.09
- 52 Week High
- PALI $4.32
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- PALI 56.45
- SNGX 77.06
- Support Level
- PALI $0.95
- SNGX $1.18
- Resistance Level
- PALI $1.40
- SNGX $5.38
- Average True Range (ATR)
- PALI 0.16
- SNGX 0.38
- MACD
- PALI 0.01
- SNGX 0.16
- Stochastic Oscillator
- PALI 42.65
- SNGX 37.14
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).